Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Changes in the normal maximal expiratory flow-volume curve with growth and aging.
Knudson, R. J., Lebowitz, M. D., Holberg, C. J., & Burrows, B. A. (1983) · PubMed · doi:10.1164/arrd.1983.127.6.725 · Cited by 1,907
Orens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Self-citationPrognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Natural History and Treated Course of Usual and Desquamative Interstitial Pneumonia
Carrington, C. B., Gaensler, E. A., Coutu, R. E., FitzGerald, M. X., & Gupta, R. G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804132981501 · Cited by 791
Nonspecific Interstitial Pneumonia/Fibrosis: Histologic Features and Clinical Significance
Katzenstein, A.-L. A., & Fiorelli, R. F. (1994) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199402000-00003 · Cited by 755
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Christie, J. D., Edwards, L. B., Kucheryavaya, A. Y., Aurora, P., Dobbels, F., Kirk, R., Rahmel, A. O., Stehlik, J., & Hertz, M. I. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.08.004 · Cited by 674
Cited by
Noth, I., Zhang, Y., Ma, S.-F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 614
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295
Self-citationContributions of alveolar epithelial cell quality control to pulmonary fibrosis
Katzen, J., & Beers, M. F. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139519 · Cited by 287
Chambers, D. C., Enever, D., Ilic, N., Sparks, L., Whitelaw, K., Ayres, J., Yerkovich, S. T., Khalil, D., Atkinson, K. M., & Hopkins, P. M. A. (2014) · Respirology · doi:10.1111/resp.12343 · Cited by 278
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management
Wijsenbeek, M., Kreuter, M., Olson, A., Fischer, A., Bendstrup, E., Wells, C. D., Denton, C. P., Mounir, B., Zouad-Lejour, L., Quaresma, M., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1647040 · Cited by 261
Physiology of the lung in idiopathic pulmonary fibrosis
Plantier, L., Cazes, A., Dinh-Xuan, A.-T., Bancal, C., Marchand-Adam, S., & Crestani, B. (2018) · European Respiratory Review · doi:10.1183/16000617.0062-2017 · Cited by 259
Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312346 · Cited by 227
“[19] found that a substantial percentage (25% at 10 years following initial diagnosis) of patients with IPF have long-term survival without transplantation; these patients tend to have better preserved values for FVC and diffusion capacity for carbon monoxide (DLCO) when they have initial pulmonary function testing at…”
BackgroundLancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000397 · Cited by 209
Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis
Jacob, J., Bartholmai, B. J., Rajagopalan, S., van Moorsel, C. H. M., van Es, H. W., van Beek, F. T., Struik, M. H. L., Kokosi, M., Egashira, R., Brun, A. L., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2174oc · Cited by 198
Natural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191
A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis
Bauer, Y., Tedrow, J., de Bernard, S., Birker-Robaczewska, M., Gibson, K. F., Guardela, B. J., Hess, P., Klenk, A., Lindell, K. O., Poirey, S., et al. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0310oc · Cited by 182
Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis
Kannengiesser, C., Borie, R., Ménard, C., Réocreux, M., Nitschké, P., Gazal, S., Mal, H., Taillé, C., Cadranel, J., Nunes, H., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00040115 · Cited by 162
Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-139 · Cited by 151
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
Huang, Y., Ma, S.-F., Espindola, M. S., Vij, R., Oldham, J. M., Huffnagle, G. B., Erb-Downward, J. R., Flaherty, K. R., Moore, B. B., White, E. S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1525oc · Cited by 142
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00230-2018 · Cited by 141
Nathan, S. D., du Bois, R. M., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Noble, P. W., Sahn, S. A., Valeyre, D., Weycker, D., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.008 · Cited by 114
“In the absence of validated and practical clinical instruments for measuring dyspnea and HRQOL in patients with IPF, the 6MWT may serve as a useful benchmark for assessing the degree to which one’s ability to engage in activities that affect one’s quality of life may be impaired.”
InfluentialSelf-citationDifferential role of regulatory T cells in early and late stages of pulmonary fibrosis
Boveda-Ruiz, D., D’Alessandro-Gabazza, C. N., Toda, M., Takagi, T., Naito, M., Matsushima, Y., Matsumoto, T., Kobayashi, T., Gil-Bernabe, P., Chelakkot-Govindalayathil, A.-L., et al. (2013) · Immunobiology · doi:10.1016/j.imbio.2012.05.020 · Cited by 110
Maher, T. M., Molina-Molina, M., Russell, A.-M., Bonella, F., Jouneau, S., Ripamonti, E., Axmann, J., & Vancheri, C. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0468-5 · Cited by 108
Evaluating disease severity in idiopathic pulmonary fibrosis
Robbie, H., Daccord, C., Chua, F., & Devaraj, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0051-2017 · Cited by 93
O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000108 · Cited by 75
“9 10 – 13 Clinical events such as acute exacerbations of IPF are associated with high morbidity and mortality, 14 – 16 but their frequency and signi fi cance have not been well characterised in multicentre studies.”
BackgroundEffect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W. (2019) · Respiratory Research · doi:10.1186/s12931-019-1021-2 · Cited by 43
Pirfenidone Clinical Study Group in Japan, Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01582-y · Cited by 36
Hahn, A. D., Carey, K. J., Barton, G. P., Torres, L. A., Kammerman, J., Cadman, R. V., Lee, K. E., Schiebler, M. L., Sandbo, N., & Fain, S. B. (2022) · Radiology · doi:10.1148/radiol.211433 · Cited by 33
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10
Metadata
- Authors
- Nathan, S. D., Shlobin, O. A., Weir, N., Ahmad, S., Kaldjob, J. M., Battle, E., Sheridan, M. J., & du Bois, R. M.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 140
- Issue
- 1
- Pages
- 221-229
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2004697839
- Cited by
- 369
- References
- 28
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.